Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations: 2021

Historic Liabilities from Discontinued Operations for Ligand Pharmaceuticals (LGND) over the last 1 years, with Dec 2021 value amounting to $55.5 million.

  • Ligand Pharmaceuticals' Liabilities from Discontinued Operations was N/A to $35.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $35.7 million, marking a year-over-year change of. This contributed to the annual value of $55.5 million for FY2021, which is N/A change from last year.
  • According to the latest figures from FY2021, Ligand Pharmaceuticals' Liabilities from Discontinued Operations is $55.5 million.
  • In the past 5 years, Ligand Pharmaceuticals' Liabilities from Discontinued Operations registered a high of $55.5 million during FY2021, and its lowest value of $55.5 million during FY2021.
  • Over the past 1 years, Ligand Pharmaceuticals' median Liabilities from Discontinued Operations value was $55.5 million (recorded in 2021), while the average stood at $55.5 million.